These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 26137787)

  • 21. Multidrug and vancomycin resistance among clinical isolates of
    Olufunmiso O; Tolulope I; Roger C
    Afr Health Sci; 2017 Sep; 17(3):797-807. PubMed ID: 29085408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group.
    Smith TL; Pearson ML; Wilcox KR; Cruz C; Lancaster MV; Robinson-Dunn B; Tenover FC; Zervos MJ; Band JD; White E; Jarvis WR
    N Engl J Med; 1999 Feb; 340(7):493-501. PubMed ID: 10021469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Investigation of reduced vancomycin susceptibility in methicillin-resistant staphylococci].
    Kuşcu F; Oztürk DB; Gürbüz Y; Tütüncü EE; Sencan I; Gül S
    Mikrobiyol Bul; 2011 Apr; 45(2):248-57. PubMed ID: 21644067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nationwide surveillance study of vancomycin intermediate Staphylococcus aureus strains in Korean hospitals from 2001 to 2006.
    Chung G; Cha J; Han S; Jang H; Lee K; Yoo J; Yoo J; Kim H; Eun S; Kim B; Park O; Lee Ys
    J Microbiol Biotechnol; 2010 Mar; 20(3):637-42. PubMed ID: 20372039
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Cloxacillin-susceptible Staphylococcus aureus with high MIC to glycopeptides. Ever we use cloxacillin?].
    Morales-Cartagena A; Lalueza A; San Juan R; Aguado JM
    Rev Esp Quimioter; 2015 Sep; 28 Suppl 1():25-9. PubMed ID: 26365730
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Colonization with methicillin-resistant Staphylococcus aureus in ICU patients: morbidity, mortality, and glycopeptide use.
    Garrouste-Orgeas M; Timsit JF; Kallel H; Ben Ali A; Dumay MF; Paoli B; Misset B; Carlet J
    Infect Control Hosp Epidemiol; 2001 Nov; 22(11):687-92. PubMed ID: 11842988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative activity of tedizolid and glycopeptide combination therapies for the treatment of Staphylococcus aureus infections: an in vitro and in vivo evaluation against strains with reduced susceptibility to glycopeptides.
    Betts JW; Abdul Momin HF; Phee LM; Wareham DW
    J Med Microbiol; 2018 Feb; 67(2):265-271. PubMed ID: 29300156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital.
    Sancak B; Ercis S; Menemenlioglu D; Colakoglu S; Hasçelik G
    J Antimicrob Chemother; 2005 Sep; 56(3):519-23. PubMed ID: 16046461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Staphylococcus aureus with reduced susceptibility to vancomycin.
    Cosgrove SE; Carroll KC; Perl TM
    Clin Infect Dis; 2004 Aug; 39(4):539-45. PubMed ID: 15356818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA.
    Horne KC; Howden BP; Grabsch EA; Graham M; Ward PB; Xie S; Mayall BC; Johnson PD; Grayson ML
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3447-52. PubMed ID: 19506056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A report on the first case of vancomycin-intermediate Staphylococcus aureus (VISA) in Hawai'i.
    Chaiwongkarjohn S; Pramyothin P; Suwantarat N; Bankowski MJ; Koyamatsu T; Seifried SE; Bello EF
    Hawaii Med J; 2011 Nov; 70(11):233-6. PubMed ID: 22162601
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus using an in vitro model.
    Zhanel GG; Rossnagel E; Nichol K; Cox L; Karlowsky JA; Zelenitsky S; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2011 Jun; 66(6):1301-5. PubMed ID: 21429940
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Sanprasitthiprasong Hospital.
    Panomket P; Thirat S; Wanram S; Sranujit RP
    J Med Assoc Thai; 2014 Apr; 97 Suppl 4():S7-11. PubMed ID: 24851558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.
    Smith JR; Barber KE; Hallesy J; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5529-34. PubMed ID: 26124162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vancomycin-resistant Staphylococcus aureus: a real and present danger?
    Hamilton-Miller JM
    Infection; 2002 Jun; 30(3):118-24. PubMed ID: 12120934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MRSA--the tip of the iceberg.
    Appelbaum PC
    Clin Microbiol Infect; 2006 Apr; 12 Suppl 2():3-10. PubMed ID: 16524422
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Antibiotic susceptibility of Staphylococcus aureus strains isolated in two university hospitals in Rabat, Morocco].
    Elhamzaoui S; Benouda A; Allali F; Abouqual R; Elouennass M
    Med Mal Infect; 2009 Dec; 39(12):891-5. PubMed ID: 19269758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro activity of oritavancin against community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA).
    Saravolatz LD; Pawlak J; Johnson LB
    Int J Antimicrob Agents; 2010 Jul; 36(1):69-72. PubMed ID: 20413274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resistance or decreased susceptibility to glycopeptides, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus.
    Nannini E; Murray BE; Arias CA
    Curr Opin Pharmacol; 2010 Oct; 10(5):516-21. PubMed ID: 20598637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital.
    Garnier F; Chainier D; Walsh T; Karlsson A; Bolmström A; Grelaud C; Mounier M; Denis F; Ploy MC
    J Antimicrob Chemother; 2006 Jan; 57(1):146-9. PubMed ID: 16286482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.